NCT05499390
进行中（未招募）
3 期
A Randomized Controlled, Multi-center Phase III Clinical Trial of AK112 Versus Pembrolizumab as First-line Treatment for PD-L1-Positive Locally-Advanced or Metastatic Non-Small Cell Lung Cancer
概览
- 阶段
- 3 期
- 干预措施
- AK112
- 疾病 / 适应症
- Advanced Non-small-cell Lung Cancer
- 发起方
- Akeso
- 入组人数
- 398
- 试验地点
- 1
- 主要终点
- PFS assessed by IRRC per RECIST v1.1
- 状态
- 进行中（未招募）
- 最后更新
- 上个月
概览
简要总结
This trial is a Phase III study. All patients are stage IIIB/C (unsuitable for radical therapy) or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 comparing Pembrolizumab in subjects with advanced NSCLC whose tumors have a programmed cell death-ligand 1 (PD-L1) Tumor Proportion Score (TPS) greater than or equal to 1%.
研究者
入排标准
入选标准
- •Has a histologically or cytologically confirmed diagnosis of NSCLC.
- •Has Stage IIIB/C or IV NSCLC (American Joint Committee on Cancer \[AJCC\]).
- •≥18 years old (at the time consent is obtained).
- •Be able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures).
- •Be able to provide formalin fixed, paraffin-embedded (FFPE) tumor tissue.
- •Has a life expectancy of at least 3 months.
- •Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as determined by the site study team.
- •Has no EGFR-sensitive mutations or ALK gene translocations.
- •Has positive PD-L1 expression in tumor tissue.
排除标准
- •Has any histologically small cell carcinoma component.
- •Is currently participating in a study of an investigational agent or using an investigational device.
- •Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy within 2 years prior to the first dose of study treatment.
- •Has undergone major surgery within 30 days of Study Day
- •Has a known additional malignancy that is progressing or requires systemic treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
- •Has known active central nervous system (CNS) metastases.
- •Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
- •Has an active infection requiring systemic therapy.
- •Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \[qualitative\] is detected).
- •History of myocardial infarction, unstable angina, congestive heart failure within 12 months prior to day 1 of study treatment.
研究组 & 干预措施
AK112
Subjects receive AK112 monotherapy intravenously (IV), selected dose.
干预措施: AK112
Pembrolizumab
Subjects receive Pembrolizumab monotherapy intravenously (IV), 200mg q3w.
干预措施: Pembrolizumab
结局指标
主要结局
PFS assessed by IRRC per RECIST v1.1
时间窗: Up to 2 approximately years
Progression-free survival (PFS) is defined as the time from the date of randomization till the first documentation of disease progression (per RECIST v1.1 criteria) assessed by the blinded IRRC or death due to any cause (whichever occurs first).
次要结局
- DoR assessed by the investigator per RECIST v1.1(Up to 2 approximately years)
- TTR assessed by the investigator per RECIST v1.1(Up to 2 approximately years)
- ORR assessed by IRRC per RECIST v1.1(Up to 2 approximately years)
- ORR assessed by the investigator per RECIST v1.1(Up to 2 approximately years)
- OS(Up to 2 approximately years)
- DoR assessed by IRRC per RECIST v1.1(Up to 2 approximately years)
- DCR assessed by IRRC per RECIST v1.1(Up to 2 approximately years)
- TTR assessed by IRRC per RECIST v1.1(Up to 2 approximately years)
- PFS assessed by investigator per RECIST v1.1(Up to 2 approximately years)
- AE(Up to 2 approximately years)
- ADA(Up to 2 approximately years)
- PD-L1 expression(Up to 2 approximately years)
- DCR assessed by the investigator per RECIST v1.1(Up to 2 approximately years)
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
3 期
AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung CancerAdvanced Squamous Non Small Cell Lung CancerNCT05840016Akeso532
进行中（未招募）
3 期
AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract CancerBiliary Tract CancerNCT06591520Akeso682
已完成
3 期
Study of NV-101 for Efficacy, Pharmacodynamics, and Safety in Dental Patients Undergoing Maxillary ProceduresAnesthesia, DentalNCT00309335Novalar Pharmaceuticals, Inc.240
Unknown
3 期
Nab-Paclitaxel Versus Paclitaxel Plus Carboplatin in Advanced Squamous Cell Non Small Cell Lung CancerNon-small Cell Lung CancerNCT03262948CSPC ZhongQi Pharmaceutical Technology Co., Ltd.388
已完成
3 期
A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus SecretionsRespiratory Tract DiseasesAbnormal Mucus SecretionsNCT03843541Zambon SpA333
相关资讯
Ivonescimab Receives China Approval for EGFR-Mutated NSCLC, Demonstrates Superior Efficacy Across Multiple Cancer Types- Ivonescimab, a novel bispecific antibody targeting both PD-1 and VEGF, received approval from China's National Medical Products Administration in May 2024 for EGFR-mutated advanced non-squamous NSCLC following tyrosine kinase inhibitor failure.
- Phase III clinical trials demonstrated significant progression-free survival improvements, with ivonescimab plus chemotherapy achieving 7.06 months versus 4.80 months for chemotherapy alone in EGFR-mutated NSCLC patients.
- The drug showed promising efficacy across multiple cancer types including triple-negative breast cancer (72.4% response rate), small cell lung cancer (80% response rate), and biliary tract cancer (63.6% response rate).
- Ivonescimab's unique tetravalent structure enables cooperative binding where VEGF presence enhances PD-1 binding affinity by 18-fold compared to conventional monoclonal antibodies.Aumolertinib Shows Promise in NSCLC, Ivonescimab Outperforms Pembrolizumab, and Novel Therapies Emerge in Breast Cancer and Multiple Myeloma- Aumolertinib demonstrated improved progression-free survival in unresectable stage III EGFR-mutated NSCLC patients post-chemoradiation therapy in the phase 3 POLESTAR trial.
- Ivonescimab reduced the risk of disease progression or death in PD-L1-positive advanced NSCLC compared to pembrolizumab in the phase 3 HARMONi-2 trial.
- Oral SERDs and PROTACs are providing additional treatment options for breast cancer, especially in the post-CDK4/6 inhibitor setting, according to Erika Hamilton, MD.
- CAR T-cell therapy, such as idecabtagene vicleucel, shows promise in relapsed multiple myeloma, with careful management of cytokine release syndrome (CRS).